Related Experiment Video
Updated: Oct 4, 2025

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Is There a Role for Triple Therapy After ACS?
Sukhdeep Bhogal1, Mohamad Alkhouli2, Christopher J White3
1Medstar Washington Hospital Center, Washington, DC, USA.
Purpose Of Review:
The optimal antithrombotic strategy in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) remains the subject of controversy. In this article, we review the current evidence for the use of triple therapy in acute coronary syndrome (ACS) patients.
Recent Findings:
The recently published trials of AF patients undergoing PCI have shown that combination of non-vitamin K oral anticoagulants (NOACs) with an antiplatelet agent is either superior or non-inferior to vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT) in reducing bleeding complications with no difference in regard to thromboembolic events. Currently, the use of dual therapy (preferably with a NOAC and clopidogrel) is recommended over triple therapy in these patients. The optimal duration should be guided by the assessment of an individual's risk of thrombosis and bleeding events.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Atherosclerosis III: Management
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome V: Nursing Management

